MAIA Biotechnology Announces Year-to-Date Highlights And Achievements, Including Clinical Progress Of Lead Candidate THIO, A First-In-Class Cancer Telomere Targeting Agent For Non-Small Cell Lung Cancer (NSCLC)
Portfolio Pulse from Benzinga Newsdesk
MAIA Biotechnology has announced significant year-to-date achievements, including clinical progress of its lead candidate THIO, a first-in-class cancer telomere targeting agent for non-small cell lung cancer (NSCLC). The company has secured over $12 million in funding, with $7.4 million raised in Q2'24. THIO has shown exceptional efficacy in Phase 2 clinical trials, with a 38% overall response rate and a median progression-free survival of 5.5 months, outperforming current standard-of-care treatments.
June 06, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MAIA Biotechnology has made significant strides with its lead candidate THIO for NSCLC, securing over $12 million in funding and demonstrating strong clinical trial results. THIO's 38% overall response rate and 5.5 months median progression-free survival in Phase 2 trials significantly outperform current treatments.
The strong clinical trial results and substantial funding secured by MAIA Biotechnology are likely to positively impact its stock price in the short term. The 38% ORR and 5.5 months PFS for THIO in NSCLC are significantly better than current treatments, indicating a strong value proposition for investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100